Peptide Bio IndexEvidence first. Hype last.
⌕

Retatrutide Receptor Pharmacology: GLP-1, GIP, and Glucagon Signaling

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited8 min readUpdated Sep 6, 2026
Jump to a section
  1. Overview: retatrutide described as a triple (GIP/GLP-1/glucagon) receptor agonist
  2. Reported pharmacologic actions and clinical correlates
  3. Clinical pharmacology signals from Phase 2 trials
  4. Safety and physiologic effects plausibly related to receptor activation
  5. Preclinical and mechanistic summaries reported in reviews
  6. Gaps in receptor-level pharmacology and comparative data
  7. Reported study-design details from cited sources
  8. Limitations and research gaps
  9. Documentation checklist
  10. Related research supplies
  11. More Retatrutide research
  12. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This deep dive summarizes how recent clinical trials and reviews characterize retatrutide's receptor pharmacology with respect to GLP-1, GIP, and glucagon signaling, and summarizes the clinical and preclinical pharmacologic signals reported in Phase 2 studies and review literature.

Overview: retatrutide described as a triple (GIP/GLP-1/glucagon) receptor agonist

Clinical trial reports and subsequent reviews consistently describe retatrutide (LY3437943, retatrutide) as a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor; this characterization appears in multiple Phase 2 clinical reports and review summaries. [S1] [S2] [S3] [S5] [S7]

Reported pharmacologic actions and clinical correlates

Clinical Phase 2 data link retatrutide dosing to large, dose-dependent reductions in body weight and improvements in glycaemic measures (for example, marked percent weight loss in obesity trials and clinically meaningful HbA1c reductions in people with type 2 diabetes), and review and trial reports associate these outcomes with activation of GIP, GLP-1, and glucagon signaling; preclinical summaries in reviews further attribute effects such as delayed gastric emptying, reduced food intake, and metabolic changes to the compound's multimodal agonism. [S2] [S3] [S1] [S5]

Clinical pharmacology signals from Phase 2 trials

Phase 2 randomized controlled trials report robust, dose-related efficacy signals: large percentage weight reductions in obesity trials and dose-dependent HbA1c lowering in people with type 2 diabetes, as summarized across trial reports and systematic reviews; these clinical readouts are the principal pharmacologic signals available in the reviewed sources. [S1] [S2] [S3] [S4] [S6]

Across trials, gastrointestinal adverse events (nausea, diarrhoea, vomiting, constipation) were the most common and were reported as dose-related; dose-dependent increases in heart rate were observed in at least one obesity Phase 2 trial (peaking at 24 weeks and declining thereafter), and other trial reports state an overall safety profile consistent with GLP-1 receptor agonists and combined incretin agonists. Liver-fat reductions and related metabolic changes were reported in a substudy of participants with metabolic dysfunction-associated steatotic liver disease. [S1] [S3] [S7] [S2]

Preclinical and mechanistic summaries reported in reviews

Review summaries and preclinical descriptions in the reviewed literature report that animal studies demonstrated effects such as delayed gastric emptying, reduced food intake, and weight loss, and attribute these outcomes to combined activation of GLP-1, GIP, and glucagon signaling in experimental models; these are described in review-level summaries rather than linked to detailed receptor-binding data in the reviewed excerpts. [S5]

Gaps in receptor-level pharmacology and comparative data

The reviewed clinical and review reports emphasize clinical efficacy and safety signals but do not provide the detailed receptor-level parameters (for example, in vitro binding affinities, receptor-selectivity profiles, biased signaling assays, or quantitative signaling potency at each receptor) nor direct head-to-head clinical comparisons with other incretin-based agents in the excerpts provided; systematic-review authors and commentators note the need for larger, longer, and comparative trials. [S7] [S4]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S1] Randomized, double-blind, placebo-controlled Phase 2 clinical trial Adults with obesity (BMI ≥30 or BMI 27– 1 mg; 4 mg (initial dose 2 mg or 4 mg); 8 mg (initial dose 2 mg or 4 mg); 12 mg (initial dose 2 mg) subcutaneous once weekly 48 weeks Multiple retatrutide dose groups (1 mg; 4 mg with starting-dose variants; 8 mg with starting-dose variants; 12 mg with starting-dose variants) were randomized versus placebo; primary endpoint was percent change in body weight at 24 weeks; safety and 48-week outcomes also reported.
[S2] Randomized, double-blind, placebo-controlled Phase 2a clinical trial (substudy from obesity trial) Participants with metabolic dysfunction-associated steatotic liver disease and ≥10% liver fat drawn from an obesity study 1 mg; 4 mg; 8 mg; 12 mg once-weekly subcutaneous once weekly 48 weeks Primary objective was mean relative change from baseline in liver fat at 24 weeks; liver-fat results at 24 weeks reported for 1, 4, 8, and 12 mg dose groups versus placebo.
[S3] Randomized, double-blind, placebo- and active-controlled Phase 2 clinical trial Adults with type 2 diabetes (HbA1c 7.0–10.5%, BMI 25–50 kg/m2) 0.5 mg; 4 mg (with and without escalation variants); 8 mg (with slow and fast escalation variants); 12 mg (escalation variant) once-weekly injections (route explicitly described as injections in the excerpt) once weekly assessments reported at 24 and 36 weeks; total treatment duration not explicitly stated in the reviewed excerpt Multiple retatrutide maintenance doses (including 0.5 mg, 4 mg, 8 mg, 12 mg with some escalation variants) were compared with placebo and dulaglutide; primary endpoint was change in HbA1c at 24 weeks, with additional assessments at 36 weeks.

Limitations and research gaps

  • The reviewed sources are predominantly clinical trial reports and reviews; none of the provided excerpts include primary in vitro receptor-binding constants, selectivity profiles, or intracellular signaling pathway assays for retatrutide.
  • Head-to-head clinical comparisons versus other incretin-based therapies were not reported in the provided excerpts; comparative efficacy and mechanistic superiority claims are therefore not supported by the reviewed sources.
  • Long-term safety beyond the timeframes reported in the cited Phase 2 trials (for example, beyond 48 weeks) was not available in the reviewed excerpts.
  • Some mechanistic descriptions are summary statements from reviews rather than direct primary preclinical data in the reviewed excerpts; direct preclinical experimental details are not included in the provided records.

Documentation checklist

  • Confirm primary Phase 2 trial reports and review articles that describe retatrutide as an agonist at GIP, GLP-1, and glucagon receptors.
  • Cross-reference reported clinical endpoints (body-weight change, HbA1c, liver fat) with the cited phase 2 publications.
  • Note safety signals reported in trials (gastrointestinal adverse events, heart-rate changes) and whether they are dose-related.
  • Identify missing receptor-level data in the reviewed sources (binding affinities, in vitro signaling profiles, receptor selectivity).
  • Look for head-to-head comparator trials or registries before making comparative claims; none were reported in the reviewed excerpts.
  • Temperature-monitored storage logs and inventory labeling templates
  • Laboratory refrigerator / freezer for authorized product storage (equipment reference only)
  • Surface-compatible disinfectant and wipes for general laboratory bench cleaning
  • Chain-of-custody documentation templates for trial sample handling

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: SourcePoint Research currently lists SPR-3RT for research-use-only sourcing. Review current availability and the exact batch documentation at SourcePointResearch.com. This article does not independently certify a SourcePoint batch. Peptide Bio Index is affiliated with SourcePoint Research.

More Retatrutide research

Sources and references

  1. [S1] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
  2. [S2] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.. Nature medicine. 2024. PMID: 38858523. DOI: 10.1038/s41591-024-03018-2
  3. [S3] Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.. Lancet (London, England). 2023. PMID: 37385280. DOI: 10.1016/S0140-6736(23)01053-X
  4. [S4] Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.. Proceedings (Baylor University. Medical Center). 2025. PMID: 40291085. DOI: 10.1080/08998280.2025.2456441
  5. [S5] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules. 2025. PMID: 40563436. DOI: 10.3390/biom15060796
  6. [S6] Misra S, Narayan RK, Kaur M. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.. Journal of basic and clinical physiology and pharmacology. 2025. PMID: 40728138. DOI: 10.1515/jbcpp-2025-0113
  7. [S7] Doggrell SA. Retatrutide showing promise in obesity (and type 2 diabetes).. Expert opinion on investigational drugs. 2023. PMID: 37947489. DOI: 10.1080/13543784.2023.2283020
  8. [S8] Ramsbacher N. Retatrutide.. Clinical diabetes : a publication of the American Diabetes Association. 2024. PMID: 39429457. DOI: 10.2337/cd24-0062

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts